Cavernous hemangioma. Reversible posterior leukoencephalopathy syndrome.
Taylor
I
I
Department of Neurology, Royal Melbourne Hospital, Parkville, 3050 Victoria, Australia.
D000328:Adult; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D038524:Diffusion Magnetic Resonance Imaging; D005260:Female; D006392:Hemangioma, Cavernous; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D008279:Magnetic Resonance Imaging; D008775:Methylprednisolone / Q000009:adverse effects / Q000627:therapeutic use; D009157:Myasthenia Gravis / Q000150:complications; D009778:Occipital Lobe / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D016491:Peripheral Vascular Diseases / Q000188:drug therapy* / Q000276:immunology*; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000473:pathology* / Q000503:physiopathology; D012640:Seizures / Q000209:etiology / Q000473:pathology / Q000503:physiopathology
D007166:Immunosuppressive Agents; D001379:Azathioprine; D008775:Methylprednisolone